AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE

Rhea-AI Summary

Amgen (NASDAQ:AMGN) has announced a webcasted conference call for the investment community on Tuesday, September 24, 2024, at 1:30 p.m. PT. The call will focus on discussing new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA® (inebilizumab-cdon) Phase 3 programs.

Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, along with other team members, will participate in the call. The webcast will be accessible to news media, investors, and the general public via Amgen's website at www.amgen.com under the Investors section.

The webcast will be archived and available for replay for at least 90 days after the event. Information about presentation times, webcast availability, and links can be found on Amgen's Investor Relations Events Calendar.

News Market Reaction – AMGN

-1.40%

-1.40% Session move

In the trading session that priced this news, AMGN declined 1.40%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

THOUSAND OAKS, Calif., Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024, to discuss new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA^® (inebilizumab-cdon) Phase 3 programs. Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and other members of the Amgen team will participate. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average^®, and it is also part of the Nasdaq-100 Index^®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)  

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-host-conference-call-to-discuss-new-topline-data-in-inflammation-and-rare-disease-302256043.html

SOURCE Amgen

FAQ

When is Amgen (AMGN) hosting its conference call to discuss new topline data?

Amgen (AMGN) is hosting its conference call on Tuesday, September 24, 2024, at 1:30 p.m. PT.

What clinical programs will be discussed during Amgen's (AMGN) upcoming conference call?

Amgen's conference call will discuss new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA® (inebilizumab-cdon) Phase 3 programs.

Who will be participating in Amgen's (AMGN) September 24, 2024 conference call?

Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, along with other members of the Amgen team will participate in the call.

Where can investors access Amgen's (AMGN) September 24, 2024 conference call webcast?

Investors can access the webcast on Amgen's website, www.amgen.com, under the Investors section.

How long will Amgen's (AMGN) September 24, 2024 conference call webcast be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event.